Cannabis in Europe has undergone profound changes. Once universally prohibited, the plant is now at the center of a complex policy landscape where medical use is expanding, recreational possession is decriminalized in many countries, and new regulated access models are emerging. Yet, cannabis remains the most widely consumed illicit drug on the continent, with an estimated 24 million European adults (8.4%) having used it in the last year .
This guide covers the full spectrum of cannabis in Europe: medical frameworks, recreational decriminalization, regulated access models, CBD and low-THC products, and the evolving EU legal context.
The Scale of Cannabis Use in Europe
Cannabis is the most commonly consumed illicit drug in Europe, and its market is vast. The illicit cannabis retail market in the European Union is valued at an estimated EUR 12.1 billion annually .
- Annual users: Approximately 8.4% of adults aged 15-64 (24 million people) have used cannabis in the past year .
- Daily users: An estimated 1.5% of EU adults (4.3 million people) are daily or near-daily consumers .
- Treatment admissions: Cannabis is responsible for over one-third of all drug treatment admissions in Europe, with 45% of clients entering treatment on their own initiative .
Medical Cannabis: The “Medicalization Without Legalization” Trend
A landmark 2026 study published in the Journal of Public Health identified three clinical policies for cannabis across Europe: opposition, pharmaceuticalization, and medicalization .
Medicalization Countries (22 out of 39 European countries)
Countries that have embraced medicalization recognize the herbal cannabis plant as a pharmaceutical product with medicinal attributes. These nations have established regulatory frameworks, cultivation standards, and patient access programs .
Key medicalization countries include:
- Germany (Europe’s largest medical market)
- Italy
- Poland
- The Netherlands
- Czech Republic (central oversight agency established)
- Denmark
- Malta
- Portugal
The study found a strong statistical correlation between medicalization and decriminalization of recreational use: 68% of medicalization countries have decriminalized recreational cannabis . This suggests that decriminalization facilitates patient access and fosters a medical market while avoiding the extremes of prohibition or full legalization.
Medical Cannabis Market Growth
The European medical cannabis market is projected to reach EUR 3.2 billion by 2025, with a compound annual growth rate of 67.4% . Countries like Germany have reclassified cannabis as a regular prescription medicine (2024), significantly expanding patient access . However, access remains uneven, with Germany’s imports repeatedly approaching quota limits and telemedicine practices facing increased scrutiny .
Regulated Access Models: Social Clubs and Home Cultivation
Several EU countries have moved beyond medical cannabis to create regulated access for adult use through non-commercial models.
Germany’s Cannabis Social Clubs
Since July 2024, Germany has allowed non-profit cannabis cultivation associations (social clubs) where members collectively cultivate cannabis for personal use . As of December 2025:
- 368 of 806 applications had been approved
- By late 2026, 400-600 clubs are expected to be operational
- Membership: Limited to residents with 6 months’ residency
- Monthly limit: 50g per member
- Products: Dried flowers only (no edibles or concentrates)
Germany’s original plan for commercial retail was blocked by the EU, leading to this restricted model . The new government has signaled further restrictions, particularly on the telemedicine prescription system .
Malta – The First EU Regulated Model
Malta became the first EU member to regulate cannabis in December 2021, legalizing:
- Non-profit cannabis social clubs (22 associations currently hold permits)
- Limited home cultivation
- Possession of up to 7g in private
Luxembourg – Home Cultivation and Private Use
Luxembourg legislated in July 2023 to permit limited home cultivation and private use, following Malta’s lead .
Recreational Cannabis – Decriminalization vs. Prohibition
Europe’s legal regimes for recreational cannabis fall into three categories: prohibition, decriminalization, and legalization (though full legalization remains absent in the EU) .
Decriminalization with No Penalty
| Country | Key Details | Since |
| Germany | Up to 25g in public not an offense | April 2024 |
| Czechia | Up to 25g in public not an offense | January 2026 |
| Malta | Up to 7g not an offense | December 2021 |
Decriminalization Without Incarceration
Belgium, Ireland, Italy, Latvia, Lithuania, Luxembourg, Portugal, Slovenia, and Spain (if in public) impose penalties without incarceration .
Countries Still Incarcerating
Denmark, Estonia, Greece, France, Croatia, Cyprus, Hungary, Netherlands, Austria, Poland, Romania, Slovakia, Finland, and Sweden may impose prison sentences for personal possession .
The Netherlands – The Tolerated Exception
Dutch coffeeshops are a unique model where sale of up to 5g is tolerated but not legally regulated. The supply chain to coffeeshops remains illegal (the “back-door problem”), meaning criminal groups still benefit from the trade . The Netherlands is experimenting with a closed cannabis supply chain to address this issue .
CBD and Low-THC Products
Low-THC cannabis products (below 0.2-0.3% THC) are offered for sale in most EU countries, but the regulatory approach is fragmented .
THC Limits by Country
| Country | THC Limit |
| Switzerland | 1.0% (non-EU) |
| Italy | 0.6% |
| Germany, France, Czechia | 0.2-0.3% |
| Sweden | 0.0% |
Emerging Quality Concerns
The EU Drugs Agency has identified issues with low-THC products: inconsistent CBD content, THC above legal limits, and contamination with pesticides and carcinogens . Some products sold as “high in CBD” contained enough THC to cause noticeable intoxication .
The Novel Food Uncertainty
CBD extracts are classified as novel foods under EU Regulation 2015/2283 and require authorization before marketing. To date, the European Commission has not included CBD on the authorized list, creating legal uncertainty for CBD edibles and oils .
HHC and Semi-Synthetic Cannabinoids
Semi-synthetic cannabinoids like HHC (hexahydrocannabinol) have appeared on commercial markets in parts of Europe. HHC is now controlled in at least 22 EU Member States as of February 2025, and in March 2025, the UN Commission on Narcotic Drugs placed it under the same regulations as delta-9-THC .
Cannabis Trafficking and Illicit Market
Despite legalization trends, cannabis trafficking remains a significant challenge:
- Spain plays a dominant role: 68% of all resin seized, 30% of herbal cannabis seized, and 73% of cannabis plants seized in the EU were in Spain in 2023 .
- Seizures at historic highs: Confirming high availability of the drug .
- Postal trafficking: Dutch customs intercepted 563kg of cannabis in postal packages in early 2026, mostly from the US and Canada .
- Increasing potency: Average THC in seized resin reached 23% in 2023, while herbal cannabis potency hovers around 11% .
EU Legal Developments
The Hoge Raad Reference (Case C-73/26)
In February 2026, the Dutch Supreme Court referred questions to the European Court of Justice about whether EU law prevents member states from banning the possession and importation of hemp from other EU countries when its THC content remains below the 0.3% EU threshold . This case could reshape cross-border cannabis trade across Europe.
Cannabis Policy Toolkit
The European Union Drugs Agency (EUDA) has commissioned a three-year project called Cannapol to produce a comprehensive European cannabis policy toolkit, supporting policymakers in designing and evaluating national cannabis frameworks .
Conclusion
Cannabis in Europe in 2026 is a story of diversity and evolution. Medical cannabis is expanding rapidly, with 22 countries embracing medicalization and the market projected to reach EUR 3.2 billion by 2025. Recreational decriminalization is spreading, with Germany, Czechia, and Malta removing penalties for small possession. Regulated access through social clubs is emerging as a European model, distinct from commercial legalization seen elsewhere.
Yet challenges remain: illicit trafficking persists, product quality concerns exist, and EU-level legal questions remain unresolved. The continent continues to navigate a middle path between prohibition and full legalization, with medicalization and decriminalization as the dominant trends
